<DOC>
	<DOCNO>NCT00956215</DOCNO>
	<brief_summary>The study drug , Aprepitant , currently use control chemotherapy induce nausea vomiting also approve post-operative nausea vomiting . The investigator ' evaluation morbidly obese patient demonstrate ability control nausea vomit post-operatively subset patient .</brief_summary>
	<brief_title>Decreasing Incidence Post-Operative Nausea Vomiting ( PONV ) Bariatric Patients</brief_title>
	<detailed_description>The purpose study evaluate effectiveness Aprepitant , also know Emend , reduce post-operative nausea vomit morbidly obese patient . Post-operative nausea vomit occurs morbidly obese patient greatly increase chance complication post-operative period . By treat morbidly obese patient Aprepitant , goal reduce risk complication may induce nausea vomiting .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Subjects include study must : Female At least 18 year age Nonsmoking At high risk PONV Obese BMI least 45 kg/m2 Undergoing upper gastrointestinal surgery require postoperative opioid analgesia Subjects exclude : They know allergy Aprepitant Ondansetron They currently take Orap ( pimozide ) , Seldane ( terfenadine ) , Hismanal ( astemizole ) , Propulsid ( cisapride ) They pregnant They breastfeed They plan get pregnant 2 month follow surgery They able receive patient control analgesia ( PCA ) follow surgery They know drug alcohol abuse problem They chronic nausea vomiting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>post operative</keyword>
	<keyword>obese</keyword>
</DOC>